نتایج جستجو برای: mrd

تعداد نتایج: 1567  

Journal: :Blood 2016
Bruno Paiva Luis A Corchete Maria-Belen Vidriales Noemi Puig Patricia Maiso Idoia Rodriguez Diego Alignani Leire Burgos Maria-Luz Sanchez Paloma Barcena Maria-Asuncion Echeveste Miguel T Hernandez Ramón García-Sanz Enrique M Ocio Albert Oriol Mercedes Gironella Luis Palomera Felipe De Arriba Yolanda Gonzalez Sarah K Johnson Joshua Epstein Bart Barlogie Juan José Lahuerta Joan Blade Alberto Orfao María-Victoria Mateos Jesús F San Miguel

Persistence of chemoresistant minimal residual disease (MRD) plasma cells (PCs) is associated with inferior survival in multiple myeloma (MM). Thus, characterization of the minor MRD subclone may represent a unique model to understand chemoresistance, but to our knowledge, the phenotypic and genetic features of the MRD subclone have never been investigated. Here, we compared the antigenic profi...

Journal: :Blood 2008
Michael J Borowitz Meenakshi Devidas Stephen P Hunger W Paul Bowman Andrew J Carroll William L Carroll Stephen Linda Paul L Martin D Jeanette Pullen David Viswanatha Cheryl L Willman Naomi Winick Bruce M Camitta

Minimal residual disease (MRD) is an important predictor of relapse in acute lymphoblastic leukemia (ALL), but its relationship to other prognostic variables has not been fully assessed. The Children's Oncology Group studied the prognostic impact of MRD measured by flow cytometry in the peripheral blood at day 8, and in end-induction (day 29) and end-consolidation marrows in 2143 children with ...

Journal: :Blood 2001
M Uzunel J Mattsson M Jaksch M Remberger O Ringdén

Relapse is the major cause of treatment failure after allogeneic stem cell transplantation (SCT) in patients with acute lymphoblastic leukemia. Minimal residual disease (MRD) was analyzed before SCT in 30 patients with acute lymphoblastic leukemia. The aim was to determine whether the level of MRD before transplantation was correlated with outcome. Fifteen patients were found to have high-level...

Journal: :Blood 2000
E Coustan-Smith J Sancho M L Hancock J M Boyett F G Behm S C Raimondi J T Sandlund G K Rivera J E Rubnitz R C Ribeiro C H Pui D Campana

By using rapid flow cytometric techniques capable of detecting one leukemic cell in 10(4) normal cells, we prospectively studied minimal residual disease (MRD) in 195 children with newly diagnosed acute lymphoblastic leukemia (ALL) in clinical remission. Bone marrow aspirates (n = 629) were collected at the end of remission induction therapy and at 3 intervals thereafter. Detectable MRD (ie, > ...

2011
Adriana Plesa Xavier Thomas Quoc Hung Le Anne-Sophie Michallet Valérie Dubois Charles Dumontet Mauricette Michallet

Determination of minimal residual disease (MRD) remains crucial for the follow-up after therapy in chronic lymphocytic leukemia (CLL) patients. Chimerism was assessed by short tandem repeat (STR)PCR and single nucleotide polymorphisms (SNP)PCR, and MRD by a multicolor flow cytometric approach in 12 consecutive patients with CLL after they received allogeneic stem cell transplantation (SCT). Ove...

2017
Giuseppe Gritti Chiara Pavoni Alessandro Rambaldi

After 25 years, evaluation of minimal residual disease (MRD) in follicular lymphoma (FL) has become a standardized technique frequently integrated into clinical trials for its consistent and independent prognostic significance. Achievement of a sustained MRD negativity is a marker of treatment sensibility that has been associated with excellent clinical outcome in terms of clinical response and...

Journal: :Blood 2016
Richard F Little Lisa M McShane

Measuring minimal residual disease (MRD) to detect 1 or fewer CLL cells in 10 000 normal leukocytes has consistently shown correlation with long-term clinical outcomes when examined in the context of prospective clinical trials. Substantial international effort has provided a sound scientific foundation establishing valid and reproducible methods in flow cytometry and polymerase chain reaction–...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
David Wu Ryan O Emerson Anna Sherwood Mignon L Loh Anne Angiolillo Bryan Howie Jennifer Vogt Mark Rieder Ilan Kirsch Christopher Carlson David Williamson Brent L Wood Harlan Robins

PURPOSE High-throughput sequencing (HTS) of immunoglobulin heavy-chain genes (IGH) in unselected clinical samples for minimal residual disease (MRD) in B lymphoblastic leukemia (B-ALL) has not been tested. As current MRD-detecting methods such as flow cytometry or patient-specific qPCR are complex or difficult to standardize in the clinical laboratory, sequencing may enhance clinical prognostic...

Journal: :Blood 2002
Marja J Willemse Taku Seriu Klaudia Hettinger Elisabetta d'Aniello Wim C J Hop E Renate Panzer-Grümayer Andrea Biondi Martin Schrappe Willem A Kamps Guiseppe Masera Helmut Gadner Hansjoerg Riehm Claus R Bartram Jacques J M van Dongen

We performed sensitive polymerase chain reaction-based minimal residual disease (MRD) analyses on bone marrow samples at 9 follow-up time points in 71 children with T-lineage acute lymphoblastic leukemia (T-ALL) and compared the results with the precursor B-lineage ALL (B-ALL) results (n = 210) of our previous study. At the first 5 follow-up time points, the frequency of MRD-positive patients a...

Journal: :Blood 2006
Monika Brüggemann Thorsten Raff Thomas Flohr Nicola Gökbuget Makoto Nakao Jo Droese Silke Lüschen Christiane Pott Matthias Ritgen Urban Scheuring Heinz-August Horst Eckhard Thiel Dieter Hoelzer Claus R Bartram Michael Kneba

Adult patients with acute lymphoblastic leukemia (ALL) who are stratified into the standard-risk (SR) group due to the absence of adverse prognostic factors relapse in 40% to 55% of the cases. To identify complementary markers suitable for further treatment stratification in SR ALL, we evaluated the predictive value of minimal residual disease (MRD) and prospectively monitored MRD in 196 strict...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید